239 related articles for article (PubMed ID: 36550413)
1. Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
Mahtani R; Niyazov A; Arondekar B; Lewis K; Rider A; Massey L; Lux MP
BMC Cancer; 2022 Dec; 22(1):1343. PubMed ID: 36550413
[TBL] [Abstract][Full Text] [Related]
2. Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
Mahtani R; Niyazov A; Arondekar B; Lewis K; Rider A; Massey L; Lux MP
Breast; 2022 Dec; 66():236-244. PubMed ID: 36368161
[TBL] [Abstract][Full Text] [Related]
3. Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without, or with Unknown,
Lux MP; Lewis K; Rider A; Niyazov A
Breast Care (Basel); 2022 Oct; 17(5):460-469. PubMed ID: 36684399
[TBL] [Abstract][Full Text] [Related]
4. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
Ettl J; Quek RGW; Lee KH; Rugo HS; Hurvitz S; Gonçalves A; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Markova D; Bhattacharyya H; Hannah AL; Eiermann W; Blum JL; Litton JK
Ann Oncol; 2018 Sep; 29(9):1939-1947. PubMed ID: 30124753
[TBL] [Abstract][Full Text] [Related]
5. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
[TBL] [Abstract][Full Text] [Related]
7. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.
Hurvitz SA; Quek RGW; Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke E; Mina LA; Balmaña J; Fasching PA; Bhattacharyya H; Hannah AL; Robson ME; Wardley AM
Eur J Cancer; 2018 Nov; 104():160-168. PubMed ID: 30359909
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
Zhang M; Yu X; Wang J; Li Y; Cao L
J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
[TBL] [Abstract][Full Text] [Related]
9. Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.
Mahtani R; Niyazov A; Lewis K; Rider A; Massey L; Arondekar B; Lux MP
Adv Ther; 2023 Jan; 40(1):331-348. PubMed ID: 36333567
[TBL] [Abstract][Full Text] [Related]
10. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
Litton JK; Hurvitz SA; Mina LA; Rugo HS; Lee KH; Gonçalves A; Diab S; Woodward N; Goodwin A; Yerushalmi R; Roché H; Im YH; Eiermann W; Quek RGW; Usari T; Lanzalone S; Czibere A; Blum JL; Martin M; Ettl J
Ann Oncol; 2020 Nov; 31(11):1526-1535. PubMed ID: 32828825
[TBL] [Abstract][Full Text] [Related]
11.
Mahtani R; Niyazov A; Arondekar B; Lewis K; Rider A; Massey L; Lux MP
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358816
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
Robson M; Ruddy KJ; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Li W; Tung N; Armstrong A; Delaloge S; Bannister W; Goessl C; Degboe A; Hettle R; Conte P
Eur J Cancer; 2019 Oct; 120():20-30. PubMed ID: 31446213
[TBL] [Abstract][Full Text] [Related]
13. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
Valenza C; Trapani D; Gandini S; Sposetti C; Boscolo Bielo L; Marra A; Giarratano T; Favero D; Cortesi L; Moscetti L; Pistelli M; Berardi R; Zambelli A; Lambertini M; Del Mastro L; Guarneri V; Vernieri C; Curigliano G
Eur J Cancer; 2023 Sep; 190():112944. PubMed ID: 37437366
[TBL] [Abstract][Full Text] [Related]
14. Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic
Batalini F; Madison RW; Sokol ES; Jin DX; Chen KT; Decker B; Pavlick DC; Frampton GM; Wulf GM; Garber JE; Oxnard G; Schrock AB; Tung NM
JCO Precis Oncol; 2023 Sep; 7():e2300091. PubMed ID: 37992259
[TBL] [Abstract][Full Text] [Related]
15. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC
Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics, treatment patterns, and outcomes in adult patients with germline
Obeid E; Parikh RC; Esterberg E; Arondekar B; Hitchens A; Arruda LS; Niyazov A; Whitaker K
Front Oncol; 2024; 14():1341665. PubMed ID: 38817906
[TBL] [Abstract][Full Text] [Related]
17. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
18.
Petracci FE; Villarreal-Garza C; Argañaraz F; Abuin GG; Peñaloza J; Flores MA; Piazzoni L; Riggi C; Fabiano L; González L; Cieplinski B; Rivero S; Korbenfeld E; Mandó P
Ecancermedicalscience; 2023; 17():1634. PubMed ID: 38414929
[TBL] [Abstract][Full Text] [Related]
19. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
Hurvitz SA; Gonçalves A; Rugo HS; Lee KH; Fehrenbacher L; Mina LA; Diab S; Blum JL; Chakrabarti J; Elmeliegy M; DeAnnuntis L; Gauthier E; Czibere A; Tudor IC; Quek RGW; Litton JK; Ettl J
Oncologist; 2020 Mar; 25(3):e439-e450. PubMed ID: 32162822
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
